Back to News
Market Impact: 0.3
UBS Upgrades Regeneron Pharmaceuticals to Buy from Neutral
Source: Nasdaq
Analyst InsightsCompany Fundamentals
UBS upgraded Regeneron Pharmaceuticals from Neutral to Buy on October 15, 2026. Regeneron closed at $796.34 that day, versus $778.36 on the preceding day, a gain of $17.98 (about 2.3%).
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REGN0.60
UBS0.00
More News
- Why is BE Semiconductor Industries stock sliding today?
- UBS cuts Six Flags stock price target to $18 on visitation concerns
- Halfway Through October, Diesel Is Setting the Terms for the Entire Energy Market
- BMO cuts C.H. Robinson stock price target on integration risks
- Here are the latest additions to UBS’ ’Pan-European Small & Mid-Cap’ list
- Six Flags price target cut at UBS after Georgia coaster death, but bank sees market overstating impact